World Health Organization Sounds Alert Over Acute Shortage of Obesity Medications
Less than a tenth of people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, warns the WHO as it issues its first recommendations on the therapies.
With more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The new guidance affirms that excess weight is a lifelong illness that can be treated with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to widespread availability to the treatments that can help people shift considerable weight, explains the body.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the supply of such drugs might only reach around 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages nations and manufacturers to increase availability, via measures like patent sharing.
A patent on semaglutide – the primary component of a leading brand – is due to expire in multiple nations in 2026.
The Way Obesity Drugs Work
The injections imitate a natural hormone to slow digestion, suppress the appetite and enhance satiety so people reduce food intake.
People typically start to lose weight after several weeks of commencing the weekly injections.
Evidence points to patients may regain a significant portion after a year of discontinuing the treatment, because their normal hunger come back.
Being above a healthy weight elevates your likelihood for experiencing health problems, like type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
